Publications by authors named "Zhenhang Lin"
Article Synopsis
- The study aims to find common therapeutic targets for two types of retroperitoneal liposarcoma: well-differentiated and dedifferentiated.
- Researchers analyzed clinical and gene expression data to determine survival differences and identify important genes and proteins involved in the disease.
- The results show significant survival differences between the two liposarcoma types, highlight key hub genes, and suggest four potential therapeutic drugs, paving the way for new treatment strategies.
Article Synopsis
- Fibrosarcoma is a serious type of cancer with high invasiveness and recurrence, typically treated with anthracycline drugs like doxorubicin (DOX), which may not be very effective alone.
- New strategies are being explored that combine chemotherapy with immunotherapy, specifically using a dendritic cell (DC) nanovaccine to improve treatment outcomes.
- The innovative nanovaccine, cGAMP@PLGA@CRTM, uses a unique approach that enhances immune response while minimizing side effects from low-dose DOX, presenting a promising new treatment for fibrosarcoma patients.*
Article Synopsis
- Liposarcoma is a malignant tumor from fat tissue, with this study focusing on understanding prognosis differences between retroperitoneal liposarcoma (RLPS) and non-retroperitoneal liposarcoma (NRLPS).
- Researchers used data from the SEER database and advanced statistical methods to compare survival rates and analyze genetic factors and immune microenvironment differences between RLPS and NRLPS patients.
- The findings revealed that RLPS patients generally have a worse prognosis than NRLPS patients, highlighting the need for these two types to be considered differently in clinical research and treatment strategies.
Introduction: The proportion of retroperitoneal malignant peripheral nerve sheath tumours (RMPNST) in retroperitoneal tumors is less than 5%, but the mortality rate is very high. However, there is no relevant research focused on RMPNST only.
Methods: We retrospectively analyzed data from the SEER database of patients with primary RMPNST from 2000 to 2019, by leveraging the advantages of the Seer database, we can explore the prognosis of such rare diseases.
Article Synopsis
- The research focuses on creating prognostic nomograms to predict overall survival (OS) and cancer-specific survival (CSS) for patients with primary retroperitoneal sarcoma (RPS), which has over 70 subtypes and limited existing studies on survival prediction.
- The study analyzed data from 1166 RPS patients from the SEER database and an additional 261 cases, utilizing various clinical and pathological features to develop the nomograms through multivariable Cox models.
- The validation process showed that the nomograms provided accurate predictions with good calibration and discrimination, achieving C-indices of 0.76 for OS and 0.81 for CSS, supported by strong areas under the time-dependent receiver operating characteristic curves.
Background: The murine double minute 2 (MDM2) gene is a crucial factor in the development and progression of various cancer types. Multiple rigorous scientific studies have consistently shown its involvement in tumorigenesis and cancer progression in a wide range of cancer types. However, a comprehensive analysis of the role of MDM2 in human cancer has yet to be conducted.
View Article and Find Full Text PDF